

## B-Myb, Cancer, Senescence, and MicroRNAs

Ivan Martinez<sup>1</sup> and Daniel DiMaio<sup>1,2</sup>

### Abstract

The transcription factor B-Myb plays a critical role in regulating gene expression and is implicated in controlling carcinogenesis and cellular senescence. Transcription of the *B-Myb* gene is regulated by retinoblastoma proteins acting directly on the *B-Myb* promoter. Recently, we found that microRNAs also control the abundance of *B-Myb* mRNA during senescence, adding another level of complexity to *B-Myb* regulation. This review focuses on the importance of B-Myb in cancer and senescence, with an emphasis on the regulation of B-Myb expression and activity. *Cancer Res*; 71(16); 5370–3. ©2011 AACR.

### Introduction

The *v-Myb* myeloblastosis viral oncogene homolog (avian)-like 2 (MYBL2; *B-Myb*) encodes a transcription factor that regulates the expression of numerous genes during cell cycle progression (1). The *Myb* gene family of transcription factors is present in all vertebrates (2). *c-Myb* is the homolog of the *v-Myb* oncogene, which is present in avian retroviruses that cause acute leukemia (3, 4). The other 2 family members, *A-Myb* and *B-Myb*, were cloned on the basis of homology to *c-Myb* (5). In mammals, *c-Myb* and *A-Myb* expression is restricted to specific cell types and stages of development, whereas *B-Myb* is expressed in virtually all proliferating cells (2, 5). In cultured cells, *B-Myb* expression is highest in the S-phase of the cell cycle, and changes in *B-Myb* expression have been linked to growth arrest, apoptosis, carcinogenesis, and senescence (6, 7). Thus, it is essential to determine the mechanisms that regulate expression of this important gene.

### B-Myb Regulates Genes Important in Cell Proliferation and Survival

All 3 Myb proteins bind to consensus Myb-binding sites (MBS) in DNA (2), but the phenotypes of knockout mice that lack individual *Myb* family members are strikingly different, with mice lacking *B-Myb* dying very early in development because the blastocyst inner cell mass does not form (8). These diverse phenotypes show that the Myb proteins carry out different biological functions. Divergent function of the Myb proteins was also suggested by expression profiling, which revealed that ectopic expression

of each of the 3 Myb proteins activates different sets of genes (9).

B-Myb stimulates transcription of genes that promote entry into the S- and M-phases of the cell cycle (1, 6). For several of these genes, such as DNA topoisomerase II $\alpha$  and *c-Myc*, B-Myb acts by binding directly to MBSs in their promoters (see refs. 10, 11). B-Myb activates the expression of other genes that lack MBSs, including *B-Myb* itself, by interacting with transcription factors that bind to the promoters of these genes (12, 13). In conjunction with E2F proteins, B-Myb also stimulates the expression of genes required for the G<sub>2</sub> to M-phase of the cell cycle (14). In addition, binding of B-Myb to the multiprotein LINC/DREAM complex regulates the ability of this complex to affect gene expression (15–18). B-Myb can also negatively repress gene expression, perhaps by competing with other transcription factors whose binding sites overlap with MBSs in target promoters (see refs. 19, 20). Finally, B-Myb associates directly with clathrin and filamin, components of the mitotic spindle (21). The absence of B-Myb reduces the amount of clathrin in the spindle and causes mitotic arrest.

The transcriptional activity of B-Myb is regulated by post-translational modifications and by interactions with other proteins (1). B-Myb is activated by phosphorylation and acetylation, which release it from transcriptional corepressors (22, 23). However, phosphorylation also leads to ubiquitylation of the B-Myb protein (24), decreasing its half-life and limiting its activity to S-phase. B-Myb activity is also regulated by binding to transcriptional coactivators, corepressors, and other proteins (reviewed in ref. 6).

### B-Myb in Cancer and Senescence

Given the provenance of *c-Myb* as a cellular proto-oncogene and the ability of B-Myb to regulate the expression of cell cycle genes, it is not surprising that B-Myb is involved in cell proliferation and carcinogenesis. *B-Myb* expression is required for entry into S-phase and can overcome growth inhibitory signals (25–27). Cytogenetic analysis of several types of cancers revealed amplification of chromosome 20q13, where *B-Myb* is located (see ref. 28). In addition, *B-Myb* overexpression

**Authors' Affiliations:** <sup>1</sup>Department of Genetics and <sup>2</sup>Yale Comprehensive Cancer Center, Yale School of Medicine, New Haven, Connecticut

**Corresponding Author:** Daniel DiMaio, Yale School of Medicine, P.O. Box 208005, New Haven, CT 06520-8005. Phone: 203-785-2684; Fax: 203-785-6765; E-mail: daniel.dimaio@yale.edu

doi: 10.1158/0008-5472.CAN-11-1044

©2011 American Association for Cancer Research.

occurs in several cancers and has been linked to aggressive tumor growth and poor outcomes in neuroblastomas and other tumors (28–30). Conversely, *B-Myb* repression can inhibit the proliferation of normal and tumor cells (11, 26, 31, 32). The ability of B-Myb to increase the expression of anti-apoptotic genes such as Bcl2, survivin, and clusterin may also contribute to cancer progression (17, 33–35). Interestingly, certain inherited sequence variants of *B-Myb* are associated with altered cancer risk (30, 36).

Cellular senescence, a form of irreversible growth arrest, seems to be an important obstacle that cells must bypass during carcinogenesis (37). Because *B-Myb* expression is strongly repressed during senescence, it seems reasonable that loss of B-Myb expression may play an important role in senescence. Several findings support this hypothesis. Repression of *B-Myb* inhibits proliferation of mouse BALB/c 3T3 fibroblasts, whereas constitutive *B-Myb* expression allows the cells to grow with reduced growth factors (32). In primary mouse embryonic fibroblasts, overexpression of the *ras* oncogene induces premature senescence, but coexpression of *B-Myb* abrogates this response (20). Our group previously showed that inhibition of *B-Myb* expression by short hairpin RNAs (shRNA) induces senescence in primary human fibroblasts and HeLa cervical cancer cells (38). In human embryonic lung fibroblasts, B-Myb is a direct transcriptional repressor of the cyclin-dependent kinase inhibitor p16<sup>INK4a</sup>, which is involved in the induction of senescence (39). Overexpression of *B-Myb* in these cells increases their *in vitro* lifespan, and *B-Myb* repression induces premature senescence. Taken together, these data suggest that B-Myb plays a central role in controlling senescence.

### B-Myb Is Regulated at the Posttranscriptional Level by MicroRNAs during Senescence

*B-Myb* expression is low in quiescent cells because of retinoblastoma (Rb)-mediated repression (7). Repressive complexes between members of the E2F family and the Rb family (specifically E2F4/p107 and E2F4/p130) bind to E2F sites in the *B-Myb* promoter in G<sub>0</sub> cells and repress its activity (40). Recently, our group discovered that *B-Myb* is also repressed at the posttranscriptional level by microRNAs (41).

Small noncoding microRNAs regulate gene expression by base-pairing with specific mRNA targets and affecting their translation or stability. We found that the expression of approximately 50 cellular microRNAs changes in HeLa cells undergoing Rb-induced senescence. Several members of the miR-29 and miR-30 families are upregulated in senescent HeLa cells and primary human foreskin fibroblasts. This upregulation is Rb dependent and likely to involve the oncogene *c-Myc*. It has been shown that *c-Myc* binds directly to the miR-29 and miR-30 promoters and acts as a transcriptional repressor of these genes (42). However, *c-Myc* itself is an E2F-responsive gene repressed by the Rb pathway during senescence (43). Taken together, these data suggest that miR-29 and miR-30 upregulation during senescence is due to Rb-driven inhibition of *c-Myc*

expression and the consequent loss of *c-Myc*-mediated repression of the promoters controlling transcription of these microRNAs.


By using reporter constructs, mutational analysis of microRNA binding sites, and ectopic expression or inhibition of members of the miR-29 and miR-30 families, we showed that these microRNAs bind to the 3' untranslated region (UTR) of *B-Myb* mRNA during senescence and reduce the amount of this mRNA, presumably by reducing its stability. Furthermore, overexpression of miR-29 and miR-30 inhibits the expression of endogenous *B-Myb* and reduces DNA synthesis. The inhibition of DNA synthesis by these microRNAs was partially rescued by exogenous expression of *B-Myb*, suggesting that *B-Myb* repression is responsible, at least in part, for growth inhibition in cells overexpressing miR-29 and miR-30. Finally, antagonizing the activity of miR-29 and miR-30 allows a population of cells to escape Rb-induced senescence, showing the importance of miR-29 and miR-30 in this process.

These experiments show the complexity of *B-Myb* regulation during Rb-induced senescence (Fig. 1). Activation of the Rb pathway mobilizes p107 and p130, which, in complex with E2F4, bind to the *B-Myb* promoter and inhibit transcription. In addition, Rb activation increases the expression of miR-29 and miR-30, which bind to *B-Myb* mRNA and destabilize it. As noted above, B-Myb is also regulated at the protein level by posttranslational modification and association with other cellular proteins. Presumably, this 3-tiered regulation of *B-Myb* evolved to ensure profound inhibition of B-Myb activity and complete blockade of cell cycle progression.

miR-29 and miR-30 affect the expression of numerous genes in addition to *B-Myb*, and many of these targets may also play a role in senescence or carcinogenesis. For example, Fabbri and colleagues have identified DNA methyltransferase 3A and 3B as targets of miR-29 (44). Similarly, in addition to miR-29 and miR-30, numerous microRNAs are upregulated or downregulated during senescence (41). These microRNAs may also regulate the expression of genes involved in senescence.

### Conclusions and Perspectives

B-Myb exerts powerful effects on cell behavior. The multitude of B-Myb protein partners and target genes allows it to regulate many important cellular processes, including proliferation, senescence, apoptosis, and mitosis. On the basis of this spectrum of activities and the association of B-Myb with human cancer, it may be possible to exploit B-Myb as an important prognostic, diagnostic, and therapeutic tool. Do mutations that affect the binding of Rb proteins to the *B-Myb* promoter or the binding of microRNAs to *B-Myb* mRNA affect cancer risk by regulating levels of B-Myb? Is the presence of such mutations or the level of B-Myb itself an informative biomarker? Is it possible to influence the activity of B-Myb and affect cellular behavior by modulating its expression or its ability to bind to DNA or its protein partners, including components of the LINC/DREAM



**Figure 1.** Three-tiered control of B-Myb. Activation of the Rb pathway during senescence restricts B-Myb action at multiple levels. At the DNA level, activating E2F complexes at the B-Myb promoter are replaced by inhibitory complexes between E2F4 and p107 and p130. At the RNA level, elevated levels of miR-29 and miR-30 base-pair to the 3' UTR of B-Myb mRNA, reducing its abundance. At the protein level, reduced expression of B-Myb-responsive genes lowers cyclin-cdk activity and the extent of activating phosphorylation of B-Myb. In addition, ubiquitination and degradation of B-Myb, as well as preferential association with corepressors, may further inhibit its ability to activate target genes.

complex and the mitotic spindle? Can as-yet-unrecognized layers of complexity in the regulation of B-Myb be exploited therapeutically? The central role played by B-Myb in cellular proliferation and related processes suggests that the factors that regulate the expression and activity of B-Myb deserve special scrutiny in attempts to develop rational approaches to control cancer.

#### Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

#### References

- Joaquin M, Watson RJ. Cell cycle regulation by the B-Myb transcription factor. *Cell Mol Life Sci* 2003;60:2389–401.
- Oh IH, Reddy EP. The myb gene family in cell growth, differentiation and apoptosis. *Oncogene* 1999;18:3017–33.
- Roussel M, Saule S, Lagrou C, Rommens C, Beug H, Graf T, et al. Three new types of viral oncogene of cellular origin specific for haematopoietic cell transformation. *Nature* 1979;281:452–5.
- Shen-Ong GL. The myb oncogene. *Biochim Biophys Acta* 1990;1032:39–52.
- Nomura N, Takahashi M, Matsui M, Ishii S, Date T, Sasamoto S, et al. Isolation of human cDNA clones of myb-related genes, A-myb and B-myb. *Nucleic Acids Res* 1988;16:11075–89.
- Sala A. B-MYB, a transcription factor implicated in regulating cell cycle, apoptosis and cancer. *Eur J Cancer* 2005;41:2479–84.
- Lam EW, Bennett JD, Watson RJ. Cell-cycle regulation of human B-myb transcription. *Gene* 1995;160:277–81.
- Tanaka Y, Patestos NP, Maekawa T, Ishii S. B-myb is required for inner cell mass formation at an early stage of development. *J Biol Chem* 1999;274:28067–70.
- Ness SA. Myb protein specificity: evidence of a context-specific transcription factor code. *Blood Cells Mol Dis* 2003;31:192–200.
- Brandt TL, Fraser DJ, Leal S, Halandras PM, Kroll AR, Kroll DJ. c-Myb trans-activates the human DNA topoisomerase IIalpha gene promoter. *J Biol Chem* 1997;272:6278–84.
- Gualdrini F, Corvetta D, Cantilena S, Chayka O, Tanno B, Raschella G, et al. Addition of MYCN amplified tumours to B-MYB underscores a reciprocal regulatory loop. *Oncotarget* 2010;1:278–88.
- Foos G, Natour S, Klempnauer KH. TATA-box dependent trans-activation of the human HSP70 promoter by Myb proteins. *Oncogene* 1993;8:1775–82.
- Sala A, Saitta B, De Luca P, Cervellera MN, Casella I, Lewis RE, et al. B-MYB transactivates its own promoter through SP1-binding sites. *Oncogene* 1999;18:1333–9.

#### Acknowledgments

We thank Joan Steitz and members of the DiMaio laboratory for critical reading of the manuscript.

#### Grant Support

Work conducted in the authors' laboratory was supported by a grant from the National Cancer Institute (CA016038).

Received March 28, 2011; revised May 6, 2011; accepted May 12, 2011; published online August 9, 2011.

14. Zhu W, Giangrande PH, Nevins JR. E2Fs link the control of G1/S and G2/M transcription. *EMBO J* 2004;23:4615–26.
15. Litovchick L, Sadasivam S, Florens L, Zhu X, Swanson SK, Velmurugan S, et al. Evolutionarily conserved multisubunit RBL2/p130 and E2F4 protein complex represses human cell cycle-dependent genes in quiescence. *Mol Cell* 2007;26:539–51.
16. Schmit F, Korenjak M, Mannefeld M, Schmitt K, Franke C, von Eyss B, et al. LINC, a human complex that is related to pRB-containing complexes in invertebrates regulates the expression of G2/M genes. *Cell Cycle* 2007;6:1903–13.
17. Knight AS, Notaridou M, Watson RJA. A Lin-9 complex is recruited by B-Myb to activate transcription of G2/M genes in undifferentiated embryonal carcinoma cells. *Oncogene* 2009;28:1737–47.
18. Mannefeld M, Klassen E, Gaubatz S. B-MYB is required for recovery from the DNA damage-induced G2 checkpoint in p53 mutant cells. *Cancer Res* 2009;69:4073–80.
19. Marhamati DJ, Sonenshein GE. B-Myb expression in vascular smooth muscle cells occurs in a cell cycle-dependent fashion and down-regulates promoter activity of type I collagen genes. *J Biol Chem* 1996;271:3359–65.
20. Masselink H, Vastenhout N, Bernards R. B-myb rescues ras-induced premature senescence, which requires its transactivation domain. *Cancer Lett* 2001;171:87–101.
21. Yamauchi T, Ishidao T, Nomura T, Shinagawa T, Tanaka Y, Yonemura S, et al. A B-Myb complex containing clathrin and filamin is required for mitotic spindle function. *EMBO J* 2008;27:1852–62.
22. Johnson LR, Johnson TK, Desler M, Luster TA, Nowling T, Lewis RE, et al. Effects of B-Myb on gene transcription: phosphorylation-dependent activity and acetylation by p300. *J Biol Chem* 2002;277:4088–97.
23. Robinson C, Light Y, Groves R, Mann D, Marias R, Watson R. Cell-cycle regulation of B-Myb protein expression: specific phosphorylation during the S phase of the cell cycle. *Oncogene* 1996;12:1855–64.
24. Charrasse S, Carena I, Brondani V, Klempnauer KH, Ferrari S. Degradation of B-Myb by ubiquitin-mediated proteolysis: involvement of the Cdc34-SCF(p45Skp2) pathway. *Oncogene* 2000;19:2986–95.
25. Lin D, Fiscella M, O'Connor PM, Jackman J, Chen M, Luo LL, et al. Constitutive expression of B-myb can bypass p53-induced Waf1/Cip1-mediated G1 arrest. *Proc Natl Acad Sci U S A* 1994;91:10079–83.
26. Sala A, Casella I, Bellon T, Calabretta B, Watson RJ, Peschle C. B-myb promotes S phase and is a downstream target of the negative regulator p107 in human cells. *J Biol Chem* 1996;271:9363–7.
27. Joaquin M, Watson RJ. The cell cycle-regulated B-Myb transcription factor overcomes cyclin-dependent kinase inhibitory activity of p57 (KIP2) by interacting with its cyclin-binding domain. *J Biol Chem* 2003;278:44255–64.
28. Bar-Shira A, Pinthus JH, Rozovsky U, Goldstein M, Sellers WR, Yaron Y, et al. Multiple genes in human 20q13 chromosomal region are involved in an advanced prostate cancer xenograft. *Cancer Res* 2002;62:6803–7.
29. Raschella G, Cesi V, Amendola R, Negroni A, Tanno B, Altavista P, et al. Expression of B-myb in neuroblastoma tumors is a poor prognostic factor independent from MYCN amplification. *Cancer Res* 1999;59:3365–8.
30. Thorner AR, Hoadley KA, Parker JS, Winkel S, Millikan RC, Perou CM. In vitro and in vivo analysis of B-Myb in basal-like breast cancer. *Oncogene* 2009;28:742–51.
31. Arsurra M, Introna M, Passerini F, Mantovani A, Golay J. B-myb antisense oligonucleotides inhibit proliferation of human hematopoietic cell lines. *Blood* 1992;79:2708–16.
32. Sala A, Calabretta B. Regulation of BALB/c 3T3 fibroblast proliferation by B-myb is accompanied by selective activation of cdc2 and cyclin D1 expression. *Proc Natl Acad Sci U S A* 1992;89:10415–9.
33. Cervellera M, Raschella G, Santilli G, Tanno B, Ventura A, Mancini C, et al. Direct transactivation of the anti-apoptotic gene apolipoprotein J (clusterin) by B-MYB. *J Biol Chem* 2000;275:21055–60.
34. Grassilli E, Salomoni P, Perrotti D, Franceschi C, Calabretta B. Resistance to apoptosis in CTLL-2 cells overexpressing B-Myb is associated with B-Myb-dependent bcl-2 induction. *Cancer Res* 1999;59:2451–6.
35. Lang G, Gombert WM, Gould HJ. A transcriptional regulatory element in the coding sequence of the human Bcl-2 gene. *Immunology* 2005;114:25–36.
36. Schwab R, Bussolari R, Corvetta D, Chayka O, Santilli G, Kwok JM, et al. Isolation and functional assessment of common, polymorphic variants of the B-MYB proto-oncogene associated with a reduced cancer risk. *Oncogene* 2008;27:2929–33.
37. Ben-Porath I, Weinberg RA. The signals and pathways activating cellular senescence. *Int J Biochem Cell Biol* 2005;37:961–76.
38. Johung K, Goodwin EC, DiMaio D. Human papillomavirus E7 repression in cervical carcinoma cells initiates a transcriptional cascade driven by the retinoblastoma family, resulting in senescence. *J Virol* 2007;81:2102–16.
39. Huang Y, Wu J, Li R, Wang P, Han L, Zhang Z, et al. B-MYB delays cell aging by repressing p16 (INK4a) transcription. *Cell Mol Life Sci* 2011;68:893–901.
40. Wells J, Boyd KE, Fry CJ, Bartley SM, Farnham PJ. Target gene specificity of E2F and pocket protein family members in living cells. *Mol Cell Biol* 2000;20:5797–807.
41. Martinez I, Cazalla D, Almstead LL, Steitz JA, DiMaio D. miR-29 and miR-30 regulate B-Myb expression during cellular senescence. *Proc Natl Acad Sci U S A* 2011;108:522–7.
42. Chang TC, Yu D, Lee YS, Wentzel EA, Arking DE, West KM, et al. Widespread microRNA repression by Myc contributes to tumorigenesis. *Nat Genet* 2008;40:43–50.
43. DeFilippis RA, Goodwin EC, Wu L, DiMaio D. Endogenous human papillomavirus E6 and E7 proteins differentially regulate proliferation, senescence, and apoptosis in HeLa cervical carcinoma cells. *J Virol* 2003;77:1551–63.
44. Fabbri M, Garzon R, Cimmino A, Liu Z, Zanoni N, Callegari E, et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. *Proc Natl Acad Sci U S A* 2007;104:15805–10.